Publications by authors named "F V Mody"
Replications are important for assessing the reliability of published findings. However, they are costly, and it is infeasible to replicate everything. Accurate, fast, lower-cost alternatives such as eliciting predictions could accelerate assessment for rapid policy implementation in a crisis and help guide a more efficient allocation of scarce replication resources.
View Article and Find Full Text PDFBackground: In patients with heart failure with reduced ejection fraction (HFrEF), lower discharge heart rate (HR) is known to be associated with better outcomes. However, the effect of HR control on patient outcomes, and the demographic and clinical determinants of this association, are not well documented.
Objectives: The purpose of this work was to evaluate the association between the HR control and the risk of post-discharge rehospitalization in patients hospitalized with HFrEF.
Article Synopsis
- The study examined the impact of two medications, sacubitril/valsartan and ramipril, on short-term kidney function changes in patients experiencing acute myocardial infarction (MI), focusing on serum creatinine levels.
- In a trial with 5,661 patients, it was found that those taking sacubitril/valsartan had a slightly higher likelihood of experiencing initial increases in serum creatinine compared to those taking ramipril.
- However, acute changes in creatinine levels from either medication did not correlate with worse long-term cardiovascular outcomes or significant changes in kidney function, suggesting the initial increases might not indicate long-term risks.
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
Eur J Heart Fail
January 2024
Aim: It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high-risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion.
Methods And Results: Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs.
Background: Low-cost generic programs (LCGPs) that expand access to affordable cardiovascular disease (CVD) medicines can assist patients in achieving desired cardiovascular outcomes. It is important that LCGPs offer CVD medicines that promote evidence-based prescribing.
Objective: To evaluate LCGPs' coverage of evidence-based CVD medications using a clinical framework that examines coverage of core treatments, coverage of options with the highest-quality evidence, and the variety of medication options and strengths that create choices and allow dosing titration.